HedgeRoll - Value Investing and After Tax Returns
  • HedgeRoll
  • Contact
  • Research

hedgeroll

In Search of After-Tax returns

The Most Tax-Efficient Investment Strategy of All Time

4/10/2016

0 Comments

 
Back in January of 2015, I landed a meeting with a well-known value investor. While I won't name-drop him on this blog, I will say he has a career measured in decades, and should be familiar to most of my readers.

How did I land the meeting? Via cold letter, in a textbook application of "The Tim Ferriss Method" outlined in The 4-Hour Workweek. The section is called"How to Get George Bush Sr. of the CEO of Google on the Phone" (Thanks, Tim!)

And it Worked.

So there I was sitting in his conference room, waiting for him arrive. The purpose of the meeting was to learn more about value investing with an earnings power approach, rather than asset-based value investing. 

I noticed on his bookshelf: ​
  • Value Investing: Graham to Buffett and Beyond
  • The Warren Buffett CEO: Secrets from the Berkshire Hathaway Managers
  • The Little Book that Beats the Market
  • The Most Important Thing

And then the man walked in and started lecturing right away. I shut up and started taking notes:

Earnings power vs. asset-based: Asset-based investing is higher turnover, and less efficient from a tax perspective.

I was surprised; I had never given much thought to the tax implication of various value investing strategies.

He continued: Imagine that you buy a company, watch earnings power grow, and never sell. And then toward the end of your life,  you give it to charity.

How much tax will you pay? 

Me: "None", mentally noting he made no mention of dividends.

That's right; taxes will never be paid on it.

[Pause for effect]

This is essentially what [Warren Buffett]  has done. Of course, Berkshire Hathaway subsidiaries pay taxes, but shareholders do not unless they sell.

There you have it, the most tax-efficient investment strategy of all time. Total taxes paid: zero. No retirement account needed.

Our conversation meandered from there. He asked me if I'd read The Outsiders. He shared his thoughts on who are some current outsider CEOs.

​He also told me about a company he was currently buying. He wouldn't share the name, but said it had a pre-announced bad quarter with some weakness in its energy related divisions. He believed the news immaterial, and he had been researching the company and its competitors for over one year.

Based on the fact pattern, I pieced together a guess on which company he was referring to, and his 13F filing confirmed it a few months later. Less than a year later the company was acquired. 

His admin walked into the conference room exactly 30 minutes after our meeting began. My allotted time was up. I thanked him and went home to review my notes.

​Sign up for emails.

I will only email you when I have something interesting to share.
Email Marketing You Can Trust
Not investment advice. Not a solicitation to invest. Don't take candy from strangers. The links above are affiliate links, if you were to click on one and then buy something Amazon would pay me several cents.
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Picture
    This is the personal blog of Emory Redd.

    This blog is not investment advice. This is not a solicitation to invest. Don't take candy from strangers.
    Follow @Emory_R
    View my profile on LinkedIn
    BEST OF HEDGEROLL
    ACHILLION AND RA CAPITAL: MY FAVORITE TRADE

    SALIX INVESTORS LOOKING FOR A BUYOUT SHOULD BE CAUTIOUS; MORE ACCOUNTING PROBLEMS AHEAD

    BIOTECH AS BUFFETT'S WONDERFUL BUSINESS
    Get Email Updates

    Categories

    All
    13D
    13F
    13G
    Abingworth
    Accounting
    Accounting Fraud
    Achillion ACHN
    Activist
    AGN
    Aig
    Alphasimplex Group
    American Express
    Andrew Lo
    ANTH
    Anthera Pharmaceuticals
    Anthony Scaramucci
    Arbitrage
    ARC-520
    Argonaut Capital Management
    Arrowhead Research
    Artemis
    ARWR
    ASH 2014
    Avenue Capital
    AXP
    Baker Bros. Advisors
    Baker Brothers
    Barton Biggs
    Baupost Group
    BB Biotech
    Bear Stearns
    Beneish M-Score
    BenjaminJGarber.com
    Bershire Hathaway
    Bill Gross
    Biotech Hedge Fund
    Biotechnology
    Biotech Trader Handbook
    Biotech Valuation
    Black Swan
    BMY
    Bob Treue
    Bonds
    Books
    Broadfin Capital
    Bruce Greenwald
    Bubble
    Capital Returns Management
    Carl Icahn
    Carlos Slim
    Carnegie Mellon
    Celgene (CELG)
    Channel-stuffing
    Charlie Munger
    China
    Chris Levett
    Circle-of-competence
    Clive Capital
    Coca-Cola Company
    Coke KO
    Columbia Business School
    Commodities
    Contrarian Trades
    Credit
    Credit Bubble
    Cta
    Currency
    Daniel Gold
    Data Mining
    David Einhorn
    David Gerstenhaber
    David Harding
    David Tepper
    Davita Inc
    D.E. Shaw
    Deutsche Bank
    Donald Trump
    Dunn & Bradstreet DNB
    Dva
    Earnings Manipulation
    Eric Sprott
    Fabozzi-books
    Fed Day
    Federated Investors
    Fees
    Fig
    Fixed Income
    Form 4
    Fortress Investment Group Llc
    Fund Of Funds
    Gartmore
    GILD
    Gilead
    Glaxosmithkline
    Global Macro
    Gold
    Goldman Sachs
    Gotham Capital
    GSK
    HBV
    HCV
    Hedge Fund Start-up
    Hepatitis B
    Hepatitis C
    HIV
    Humor
    IBM
    IgA Nephropathy
    Inflation
    Insurance Companies
    Intellectual Property
    International Business Machines
    Izzy Englander
    Jeffrey Ubben
    JNJ
    Joel Greenblatt
    John Paulson
    Johnson & Johnson
    John W Henry
    Julian Robertson
    Kkr
    KO
    Leon Cooperman
    Loeb
    Long Term Capital Management
    Lupus
    M&A
    Man Group
    Marc Lasry
    Mellon
    Michael Bloomberg
    Michael Burry
    Michael Lewis
    Michael L Roirdan
    Michael Novogratz
    Michael Steinhardt
    Millennium Partners
    Moody's MCO
    Mr. T
    MRX
    Municipal Bonds
    Music
    Nassim Taleb
    Obama
    Occupy Wall Street
    Oil
    Omega Advisors
    Oncology
    Orbimed Advisors
    Orphan Disease
    Palo Alto Investors
    Paul Tudor Jones Iii
    Perceptive Advisors
    Pershing Square
    PG
    Pharmacyclics (PCYC)
    Phil Falcone
    Point State Capital
    Private Equity
    Procter & Gamble
    Quantitative Easing
    Quants
    QVT Financial
    RA Capital
    Redmile Group
    Return On Invested Capital
    Rob Bobman
    Robert Shiller
    Rob Goldstein
    ROIC
    Salix Pharmaceuticals SLXP
    Sanofi-Aventis
    Sebastian Mallaby
    Sec
    Seeding
    Seth Klarman
    Shorts
    Short Selling
    Short Selling Books
    Silver
    Skybridge
    SLXP
    SNY
    Stanley Druckenmiller
    Statistical Arbitrage
    St Joe Company
    Sub-Prime
    Ted Weschler
    The Barnegat Fund
    Thomas Mellon
    Traxis Partners
    Twitter
    Twitter Hedge Fund
    Valeant
    ValueAct
    Value Investing
    Vanderbilt
    VHCP Management
    Victor Niederhoffer
    VRX
    Warren Buffett
    Warren Buffett Letters
    Wells Fargo
    Wfc
    When Stocks Crash Nicely
    William Ackman
    Winton Capital Management
    Wonderful Business
    Yale University

    Archives

    December 2016
    August 2016
    June 2016
    May 2016
    April 2016
    March 2016
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    December 2014
    November 2014
    October 2014
    August 2014
    April 2014
    August 2013
    October 2012
    September 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011
    April 2011
    March 2011
    February 2011
    January 2011
    December 2010
    November 2010
    October 2010
    September 2010

    RSS Feed

Powered by Create your own unique website with customizable templates.
  • HedgeRoll
  • Contact
  • Research